Huntington National Bank Has $7.56 Million Stake in Zoetis Inc. $ZTS

Huntington National Bank lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 30.0% during the third quarter, HoldingsChannel reports. The fund owned 51,631 shares of the company’s stock after selling 22,085 shares during the quarter. Huntington National Bank’s holdings in Zoetis were worth $7,555,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Power Wealth Management LLC increased its stake in shares of Zoetis by 5.0% in the third quarter. Power Wealth Management LLC now owns 6,363 shares of the company’s stock valued at $931,000 after buying an additional 302 shares during the period. 1ST Source Bank grew its holdings in Zoetis by 19.3% during the 3rd quarter. 1ST Source Bank now owns 7,441 shares of the company’s stock worth $1,089,000 after acquiring an additional 1,204 shares during the last quarter. Andra AP fonden increased its position in Zoetis by 136.9% in the 3rd quarter. Andra AP fonden now owns 268,200 shares of the company’s stock valued at $39,243,000 after acquiring an additional 155,000 shares during the period. Hikari Tsushin Inc. lifted its holdings in shares of Zoetis by 450.0% during the third quarter. Hikari Tsushin Inc. now owns 41,494 shares of the company’s stock worth $6,071,000 after purchasing an additional 33,950 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in shares of Zoetis by 35.1% in the third quarter. Artisan Partners Limited Partnership now owns 1,004,211 shares of the company’s stock worth $146,936,000 after purchasing an additional 260,909 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $131.06 on Friday. The firm has a market cap of $55.32 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 2.00 and a beta of 0.96. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The business’s 50 day moving average price is $126.05 and its two-hundred day moving average price is $134.05. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several research analysts recently issued reports on ZTS shares. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. UBS Group set a $136.00 price objective on Zoetis in a research note on Thursday, January 29th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Finally, Bank of America raised their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.